Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD34 and CD3
- Target
- CD34 and CD3
- Molecular classification
- Sialomucin, Cell surface glycoprotein, Other, Receptor complex (Co-receptor), Signaling adaptor protein, Immunoglobulin superfamily
01
Overview
The targets "CD34 and CD3" refer to two separate and distinct molecules commonly used as cellular markers, especially in immunology and hematology. This is not a single canonical target but rather denotes a combination or a sequential marker selection in immunophenotyping. Detailed information for each individual molecule (CD34 and CD3) is provided separately. If considered as a single entry, it is incorrect as it conjoins two distinct and unrelated molecular entities with separate structure, biology, and medical relevance.
- Other names
- CD34 antigenHematopoietic progenitor cell antigen CD34My10HPCA1gp105-120T-cell surface glycoprotein CD3 complexCD3 complexTCR-CD3 complexCluster of differentiation 3
02
Mechanism of action
This entry represents a combination of two distinct molecules (CD34 and CD3). The mechanism of action would depend on which specific molecule is being targeted: for CD34, it involves depletion or selection of CD34+ cells by monoclonal antibody binding; for CD3, it involves activation (or depletion) of T-cells by agonist/antagonist antibodies or T cell redirection and cytotoxicity (with bispecific antibodies).
03
Biological functions
Cell adhesionRegulation of hematopoietic stem cell (HSC) adhesion and migrationModulation of cell-cell and cell-matrix interactionsScaffold protein for extracellular signalingImmune responseT cell activation and signalingAntigen recognition (as part of T-cell receptor complex)Signal transduction (via ITAM motifs)
04
Disease associations
Cancer (especially leukemia and solid tumor stem cells)Cardiovascular disease (angiogenesis)InflammationOther (hematopoietic disorders)Immune disorders (autoimmunity, immunodeficiencies)Infection
05
Safety considerations
Potential depletion of normal hematopoietic stem cells if targeted systemicallyLack of specificity: expression on multiple progenitor and endothelial cell typesCytokine release syndrome (CRS) from strong T cell activationRisk of immunosuppression or T cell depletion (leading to infection risk)
06
Interacting drugs
Anti-CD34 monoclonal antibodies (e.g., for cell sorting)
4 more in the full profile.
07
Biomarkers
Biomarker for hematopoietic stem/progenitor cells in bone marrow transplantationBiomarker for endothelial progenitor cells in angiogenesis studiesPan-T-cell marker for immunophenotypingUseful in monitoring immune reconstitution or lymphocyte populations in hematology/oncology
Beyond the preview
Go deeper on CD34 and CD3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34 and CD3.